Stéatoses hépatiques dysmétaboliques en 2025 : du diagnostic au traitement (notice n° 1614963)
[ vue normale ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 03306cam a2200421 4500500 |
| 005 - DATE AND TIME OF LATEST TRANSACTION | |
| control field | 20260111072549.0 |
| 041 ## - LANGUAGE CODE | |
| Language code of text/sound track or separate title | fre |
| 042 ## - AUTHENTICATION CODE | |
| Authentication code | dc |
| 100 10 - MAIN ENTRY--PERSONAL NAME | |
| Personal name | Farrugia, Marwin A. |
| Relator term | author |
| 245 00 - TITLE STATEMENT | |
| Title | Stéatoses hépatiques dysmétaboliques en 2025 : du diagnostic au traitement |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Date of publication, distribution, etc. | 2026.<br/> |
| 500 ## - GENERAL NOTE | |
| General note | 16 |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Les stéatoses hépatiques dysmétaboliques sont fréquentes dans la population française et constituent un enjeu de santé publique. Leur caractérisation est désormais facilitée grâce à l’usage de tests non invasifs évaluant la fibrose hépatique. L’ensemble des médecins devrait participer au parcours de soins des personnes avec une stéatose hépatique dysmétabolique, généralement en situation de surpoids ou d’obésité, et régulièrement atteintes d’un diabète de type 2. Les maladies cardiovasculaires, les cancers extra-hépatiques, les décompensations de cirrhose ou le carcinome hépatocellulaire constituent les principales causes de morbi-mortalité chez ces personnes. Les parcours de soins doivent encore être améliorés afin de proposer précocement une prise en charge globale de ces personnes. L’arrivée de nouvelles thérapeutiques médicamenteuses qui révolutionnent la prise en charge de l’obésité ainsi que le développement de molécules spécifiquement efficaces chez les personnes ayant une MASH fibrosante devraient faciliter la prise en charge de ces maladies. |
| 520 ## - SUMMARY, ETC. | |
| Summary, etc. | Metabolic dysfunction-associated steatotic liver disease (MASLD) is frequent in the French population and represents a public health issue. Its characterization is now easier thanks to the use of non-invasive tests that assess liver fibrosis. All clinicians should be involved in the care pathway for people with MASLD, generally overweight or obese, and often have type 2 diabetes mellitus. Cardiovascular disease, extrahepatic cancers, decompensated cirrhosis, and hepatocellular carcinoma are the leading causes of morbidity and mortality in these patients. Care pathways still need to be improved in order to offer early comprehensive care for these people. The emergence of new drug therapies, that are revolutionizing the treatment of obesity, and the development of molecules effective in people with fibrotic MASH, should facilitate the management of these diseases. |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | carcinome hépatocellulaire |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | cirrhose MASH |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | incrétines |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MASH |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MASLD |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | resmetirom |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | stéatohépatite dysmétabolique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | stéatose hépatique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | test non invasif de la fibrose hépatique |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | hepatocellular carcinoma |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | incretins |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MASH |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MASH cirrhosis |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | MASLD |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | noninvasive liver fibrosis test |
| 690 ## - LOCAL SUBJECT ADDED ENTRY--TOPICAL TERM (OCLC, RLIN) | |
| Topical term or geographic name as entry element | resmetirom |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Smati, Sarra |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Mouillot, Thomas |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Ramdour, Victoria |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Gual, Philippe |
| Relator term | author |
| 700 10 - ADDED ENTRY--PERSONAL NAME | |
| Personal name | Anty, Rodolphe |
| Relator term | author |
| 786 0# - DATA SOURCE ENTRY | |
| Note | Hépato-Gastro & Oncologie Digestive | 32 | 10 | 2026-01-05 | p. 1085-1108 | 2115-3310 |
| 856 41 - ELECTRONIC LOCATION AND ACCESS | |
| Uniform Resource Identifier | <a href="https://stm.cairn.info/revue-hepato-gastro-oncologie-digestive-2025-10-page-1085?lang=fr&redirect-ssocas=7080">https://stm.cairn.info/revue-hepato-gastro-oncologie-digestive-2025-10-page-1085?lang=fr&redirect-ssocas=7080</a> |
Pas d'exemplaire disponible.
Réseaux sociaux